Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study.

Barton P, Andronis L, Briggs A, McPherson K, Capewell S.

BMJ. 2011 Jul 28;343:d4044. doi: 10.1136/bmj.d4044.

2.

Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care.

Ford ES, Capewell S.

Annu Rev Public Health. 2011;32:5-22. doi: 10.1146/annurev-publhealth-031210-101211. Review.

3.

Cost-effectiveness of interventions to reduce dietary salt intake.

Cobiac LJ, Vos T, Veerman JL.

Heart. 2010 Dec;96(23):1920-5. doi: 10.1136/hrt.2010.199240. Epub 2010 Nov 1.

PMID:
21041840
4.

Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.

Rubinstein A, Colantonio L, Bardach A, Caporale J, Martí SG, Kopitowski K, Alcaraz A, Gibbons L, Augustovski F, Pichón-Rivière A.

BMC Public Health. 2010 Oct 20;10:627. doi: 10.1186/1471-2458-10-627.

5.

Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam.

Ha DA, Chisholm D.

Health Policy Plan. 2011 May;26(3):210-22. doi: 10.1093/heapol/czq045. Epub 2010 Sep 15.

PMID:
20843878
6.

Community programs for the prevention of cardiovascular disease: a systematic review.

Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, Hyde C.

Am J Epidemiol. 2010 Sep 1;172(5):501-16. doi: 10.1093/aje/kwq171. Epub 2010 Jul 28. Review.

PMID:
20667932
7.

Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.

Clarke PM, Fitzgerald EM.

Med J Aust. 2010 Jun 7;192(11):633-6.

PMID:
20528715
8.

A systematic review and meta-analysis on the therapeutic equivalence of statins.

Weng TC, Yang YH, Lin SJ, Tai SH.

J Clin Pharm Ther. 2010 Apr;35(2):139-51. doi: 10.1111/j.1365-2710.2009.01085.x. Review.

PMID:
20456733
9.

Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America.

Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, Labarthe DR.

Bull World Health Organ. 2010 Feb;88(2):120-30. doi: 10.2471/BLT.08.057885. Epub 2009 Dec 8.

10.

Don't use aspirin for primary prevention of cardiovascular disease.

Barnett H, Burrill P, Iheanacho I.

BMJ. 2010 Apr 21;340:c1805. doi: 10.1136/bmj.c1805. Review. No abstract available.

PMID:
20410163
11.

Cardiovascular risk perception and evidence--practice gaps in Australian general practice (the AusHEART study).

Heeley EL, Peiris DP, Patel AA, Cass A, Weekes A, Morgan C, Anderson CS, Chalmers JP.

Med J Aust. 2010 Mar 1;192(5):254-9.

PMID:
20201758
12.

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.

Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists.

JAMA. 2010 Mar 3;303(9):841-8. doi: 10.1001/jama.2010.221.

PMID:
20197530
13.

Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis.

Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM.

Ann Intern Med. 2010 Apr 20;152(8):481-7, W170-3. doi: 10.7326/0003-4819-152-8-201004200-00212. Epub 2010 Mar 1.

PMID:
20194225
14.

Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials.

De Caterina R, Scarano M, Marfisi R, Lucisano G, Palma F, Tatasciore A, Marchioli R.

J Am Coll Cardiol. 2010 Jan 19;55(3):198-211. doi: 10.1016/j.jacc.2009.07.062.

15.

Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check?

Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, Steyerberg EW, Hunink MG.

Arch Intern Med. 2010 Jan 11;170(1):27-40. doi: 10.1001/archinternmed.2009.434. Review.

PMID:
20065196
16.

Effective population-wide public health interventions to promote sodium reduction.

Mohan S, Campbell NR, Willis K.

CMAJ. 2009 Oct 27;181(9):605-9. doi: 10.1503/cmaj.090361. Epub 2009 Sep 14. Review. No abstract available.

17.

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.

Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW.

BMJ. 2009 Jun 30;338:b2376. doi: 10.1136/bmj.b2376. Review.

18.

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A.

Lancet. 2009 May 30;373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1.

20.

Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice.

Wells S, Furness S, Rafter N, Horn E, Whittaker R, Stewart A, Moodabe K, Roseman P, Selak V, Bramley D, Jackson R.

Eur J Cardiovasc Prev Rehabil. 2008 Apr;15(2):173-8. doi: 10.1097/HJR.0b013e3282f13af4.

PMID:
18391644

Supplemental Content

Support Center